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IMPORTANCE Quantification of nonperfusion (NP) and neovascularization (NV) in diabetic
retinopathy (DR) may identify better biomarkers of disease progression.
OBJECTIVE To identify demographic risk factors and markers of advanced DR that are
associated with increased areas of NP and NV in eyes with disease ranging from no DR but
diagnosed as having diabetes to proliferative DR (PDR) and to calculate a threshold total area
of NP that may be associated with an increased risk of PDR.
DESIGN, SETTING, AND PARTICIPANTS This retrospective case series was performed on
ultrawidefield fluorescein angiography (UWF FA) images from January 2009 to May 2018
at the University of Michigan Kellogg Eye Center. A total of 363 participants (651 eyes)
diagnosed as having type 1 or 2 diabetes receiving UWF FA were included. Exclusion criteria
included previous panretinal photocoagulation (PRP) and poor-quality images
(eg, vitreous hemorrhage and significant cataract).
MAIN OUTCOMES AND MEASURES The surface areas in millimeters squared of the foveal
avascular zone; total NP; NP at posterior pole, midperiphery, and far periphery; total NV;
NV at posterior pole, midperiphery, and far periphery were measured.
RESULTS Of 363 patients, most were male (205 patients [56.5%]) and white (247 [68%]) or
black (77 [21.2%]). The mean (SD) age was 59.4 (13.7) years. Seventy-six eyes with no DR, 92
with mild NPDR, 144 with moderate NPDR, 101 with severe NPDR, 220 with PDR, and 18 with
DR of unknown severity were included. Male sex had a positive association with total NP
(difference, 15.72; 95% CI, 4.83-26.61; P = .005); black race/ethnicity with total NV
(difference, 2.32; 95% CI, 0.09-4.55; P = .04); and vitreous hemorrhage with total
NP (difference, 30.00; 95% CI, 5.26-54.75; P = .02). A threshold total NP area of 77.48 mm2
(95% CI, 54.24-92.66 mm2) was identified, at greater than which patients may have an
increased risk of developing PDR (sensitivity of 59.5% and specificity of 73.6%).
CONCLUSIONS AND RELEVANCE Our results indicate NP and NV can be quantified on UWF FA.
These biomarkers interpreted with demographic risk factors may help predict disease
progression. Conclusions are limited by ascertainment and information biases because the
results are from retrospective data.
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D iabetic retinopathy (DR) is the leading cause of newcases of vision loss in adults aged 20 to 74 years.1-3 Thecriterion standard for grading DR severity is defined
by the Early Treatment Diabetic Retinopathy Study (ETDRS).4
Through the evaluation of 7 standard retinal fields, a pa-
tient’s risk of DR progression can be calculated.5 Ultrawide-
field (UWF) scanning laser ophthalmoscopy allows for imaging
of a larger area of the retina not captured previously.6,7 Stud-
ies comparing UWF imaging and ETDRS demonstrate signifi-
cantly higher severity of DR in UWF images and more areas of
nonperfusion (NP) and neovascularization (NV).8-19
With ETDRS, increasing DR severity only requires the
presence of certain pathology, such as intraretinal microvas-
cular abnormality (IRMA) and venous beading, which disre-
gards potentially valuable quantifiable information. Quanti-
fiable measurements, such as total surface area, are difficult
to measure in ETDRS for several reasons: the imaging does
not include more peripheral retina, there could be distor-
tions in the areas connecting fields, and the montage creates
an anatomically inaccurate border that may capture only
part of a biomarker.4
Better calculation of areas may improve analyses of asso-
ciations. For example, despite demographic risk factors show-
ing a strong association with DR prevalence within clinical prac-
tice, no quantifiable association linking pathologic retinal areas
to demographics has been established. However, the clinical
relevance of areas, such as the foveal avascular zone (FAZ), NP,
and NV, as biomarkers for DR has been shown.20 Identifying
a quantifiable association is particularly pertinent for periph-
eral NP and NV because they may be associated with in-
creased risk of progression.8 Similarly, quantifying the asso-
ciation between advanced DR characteristics, such as vitreous
hemorrhage (VH) and diabetic macular edema (DME), with bio-
markers could provide insight for associations with visually
significant pathology.
The objective of this study was to analyze whether cer-
tain demographic features and characteristics of advanced DR
may be associated with certain biomarkers, namely FAZ, NP,
and NV, as segmented on UWF fluorescein angiography (FA).
In addition, we determined a threshold area of NP with the
highest sensitivity and specificity for association for risk of pro-
gression to PDR. By comparing a quantifiable metric to poten-
tial risk factors, more objective patterns and trends may be es-
tablished, which may aid in more effective follow-up and
treatment for high-risk populations.
Methods
A retrospective medical record review of patients with type 2
diabetes who received UWF FA from January 2009 to May 2018
at the University of Michigan W. K. Kellogg Eye Center was con-
ducted after approval of the University of Michigan institu-
tional review board and adhering to the tenets of the Decla-
ration of Helsinki. Because this study was completed
retrospectively, a Health Insurance Portability and Account-
ability Act waiver of consent was obtained from the Univer-
sity of Michigan institutional review board.
Inclusion and Exclusion Criteria
Eligible participants met the following inclusion criteria:
18 years or older, diagnosed as having type 1 or type 2 diabe-
tes, and evaluated with a dilated fundus examination and UWF
FA at Ann Arbor, Michigan, or the Grand Blanc satellite. Im-
ages were excluded if there was evidence of panretinal pho-
tocoagulation treatment, indistinguishable areas of NV and NP
owing to poor image quality, or abundant media opacity
(eg, vitreous hemorrhage or cataracts).
Ultrawidefield FA
Images were obtained with an UWF scanning laser ophthal-
moscopy (Optos 200Tx or California; Optos PLC). To mini-
mize warping, images were projected onto a curved surface
with a nominal eye diameter of 24 mm using proprietary Op-
tos research software that may be available to clinicians in the
near future.9,15,21
Image Segmentation
All image segmentations were completed using Insight Tool-
kit SNAP (ITK-SNAP), an open-source application that allows
level set active contour segmentation of 3-dimensional im-
ages (University of North Carolina Chapel Hill, Insight
Toolkit).22 Areas were delineated manually and color-coded
to annotate FAZ, NP, and NV (Figure). All graders were masked
of all patient data. There were 4 graders (1 postundergradu-
ate researcher who performed most segmentation [more than
85% of images], 2 medical students, and 1 ophthalmology resi-
dent). Each grader underwent an extensive training with the
first 20 images reviewed in detail for accuracy, verification, and
standardization by a single retina specialist experienced in ana-
lyzing UWF images. Each image was segmented by 1 grader,
and segmentations were considered final unless there were un-
clear areas, which would then require adjudication by the reti-
nal specialist. Regions with image artifacts like eyelashes were
excluded.
Surface Area Quantification
The mechanics of the Optos research software used have pre-
viously been described.21 Foveal avascular zone, NP, and NV
surface areas were calculated for each image in millimeters
squared. Neovascularization and NP were grouped by region
Key Points
Question Which biomarkers calculated from ultrawidefield
fluorescein images of patients with diabetes are most associated
with demographic risk factors and retinopathy progression?
Findings In this case series, male sex, black race/ethnicity, and
presence of vitreous hemorrhage were most strongly associated
with greater areas of nonperfusion and neovascularization, and a
retinal nonperfusion threshold of 77.48 mm2 may be associated
with increased risk for progression. Given the study’s design,
statistical significance could not be established.
Meaning These results suggest which factors may indicate higher
risk of severe disease progression, and eyes with at least 77.48
mm2 nonperfusion are at risk of proliferative retinopathy.
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depending on their distance from the FAZ: the region within
and including 3.00 mm of the identified FAZ was classified as
posterior pole; between 3.00 mm and including 10.00 mm was
classified as midperiphery; and between 10.00 mm and in-
cluding 15.00 mm was classified as far periphery (Figure, C).
Statistical Analysis
All statistical analyses were conducted in R (R Core Team,
2019).23 For qualitative variables (eg, sex), frequencies and rela-
tive frequencies (in percentage) were calculated; for continu-
ous variables (eg, age), mean, standard deviation, and ranges
were calculated (Table 1). Both parametric and nonparamet-
ric statistics were used in the statistical comparisons. Gener-
alized estimating equations models were implemented using
the geeglm function from the R package geepack available at
the Comprehensive R Archive Network (CRAN) to determine
P values, with P less than .05 warranting further testing in a
more robust study.24 These models were used to compute lin-
ear multivariate regressions with the area segmentations as out-
comes, accounting for correlations between left and right eyes
of a single patient. Demographic factors (eye laterality, sex, race/
ethnicity, age, and type of diabetes) and features of advanced
DR (VH, DME, requirement of PPV) were x variables. Each race/
ethnicity was compared with white race/ethnicity for regres-
sion analysis. The P values are unadjusted given the scope of
this study as more hypothesis-generating instead of confir-
matory, especially because there are limited previous studies
evaluating the associations between demographics and areas
segmented from UWF imaging. Because no statistical analy-
sis plan was drafted prior to data collection, statistical signifi-
cance cannot be established from these results. Instead, an ex-
ploratory analysis with consideration of which characteristics
Figure. Representative Image Segmentation






Patient with proliferative diabetic retinopathy. A, Ultrawidefield (UWF) without segmentation. B, Manual segmentation of nonperfusion (red), neovascularization
(purple), and foveal avascular zone (green). C, Areas were totaled using the following radii (r) from the center of the foveal avascular zone: posterior pole, r 3.00 mm
or less; midperiphery, r between 3.00 and 10.00 mm; far periphery, r between 10.00 mm and 5.00 mm.
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should be studied further within a robust study (ie, factors with
P < .05) was completed.
The Youden index was calculated to determine the total
area of NP that would provide the best sensitivity and speci-
ficity in predicting PDR, using a similar technique previously
published.12 The boot package used the adjusted bootstrap per-
centile method to calculate a 95% confidence interval for the
threshold based on 10 000 resamples.25,26 The R package AUC
was used for calculating sensitivity and specificity, and the
package pROC was used for the area under the receiving op-
erating characteristic (AUC) value and 95% confidence inter-
vals using the DeLong method.27 P values were 2-tailed and
unadjusted.
Results
Demographic Characteristics of Patients
A total of 651 eyes from 363 patients (205 men and 158 wom-
en) with no DR (76 eyes), mild NPDR (92 eyes), moderate NPDR
(144 eyes), severe NPDR (101 eyes), PDR (220 eyes), or un-
known severity (18 eyes) were analyzed (Table 1). The mean
(SD) age was 59.4 (13.7) years. Mean (SD) best-corrected vi-
sual acuity logMAR was 0.34 (0.31) (Snellen equivalent 20/
43.7). The “other” race/ethnicity group included the follow-
ing races/ethnicities: Native Hawaiian, Pacific Islander,
American Indian, and Alaska Native.
Comparison of Demographic Characteristics
The strongest association in demographics and biomarkers
(Table 2) was the difference in the total area of NP between men
and women (difference, 15.72; 95% CI, 4.83-26.61; P = .005).
Other associations with P less than .05 included the differ-
ence in NP found at the midperiphery between men and
women (difference, 7.12; 95% CI, 1.98-12.26; P = .01) and NP
far periphery between Hispanic and white (difference, −16.65;
95% CI, −30.87 to −2.44; P = .02).
For NV, the difference in NV far periphery between black
and white (difference, 0.64; 95% CI, 0.18-1.10; P = .01) and other
race/ethnicity and white (difference, −0.17; 95% CI, −0.30 to
−0.4; P = .01) had the strongest associations. Total areas are
provided as supplementary material (eTable in the Supple-
ment).
Comparison of Advanced DR Features
In multiple linear regression models accounting for demo-
graphic factors, VH had the strongest association with bio-
markers (Table 3), with a positive association between VH and
total NP (difference, 30.00; 95% CI, 5.26-54.75; P = .02) and
between VH and NP in the midperiphery (difference, 12.85;
95% CI, 2.98-22.72; P = .01).
Identifying Threshold Total Area of NP for PDR
To determine the threshold total area of NP with the highest
sensitivity and specificity for association with increased PDR
risk, the total areas of NP in mild NPDR (mean, 49.2 mm2;
95% CI, 40.6-57.8), moderate NPDR (mean, 53.9 mm2; 95% CI,
46.8-60.9), severe NPDR (mean, 67.7 mm2; 95% CI, 56.3-
79.1), and PDR (mean, 101.0 mm2; 95% CI, 91.0-110.7) were cal-
culated. The threshold total area of NP that maximizes the
Youden statistic is 77.48 mm2 (95% CI, 54.24-92.66), with a
sensitivity of 59.5% and specificity of 73.6%. The AUC was 0.7
(95% CI, 0.66-0.75; P < .001) and graphed in the supplemen-
tary material (eFigure 1 in the Supplement). Additional analy-
sis attempting to achieve a higher AUC was also performed
(eFigure 2 in the Supplement).





















Type 1 61 (16.8)
Type 2 299 (82.3)
Unknown 3 (0.8)
Eyes
Severity of diabetic retinopathy
None 76 (11.7)
Mild NPDR 92 (14.1)
Moderate NPDR 144 (22.1)












Abbreviations: DME, diabetic macular edema; NPDR, nonproliferative diabetic
retinopthy; PDR proliferative diabetic retinopathy; PPV, pars plana vitrectomy;
VH, vitreous hemorrhage.
a Other races/ethnicities included Native Hawaiian, Pacific Islander, American
Indian, and Alaska Native.
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Table 2. Influence of Demographics on Biomarkers as Explored by Multiple Linear Regression Analysis
Confounding factor Biomarker Coefficient (95% CI) P value
Sex (male/female)
FAZ 0.00 (−0.13 to 0.12) .96
NP total 15.72 (4.83 to 26.61) .005
NP posterior 0.30 (−0.16 to 0.76) .20
NP mid-periphery 7.12 (1.98 to 12.26) .01
NP far-periphery 8.72 (1.61 to 15.82) .02
NV total −0.38 (−1.44 to 0.67) .48
NV posterior −0.07 (−0.25 to −0.10) .41
NV mid-periphery −0.09 (−0.92 to 0.75) .84
NV far-periphery −0.23 (−0.47 to 0.02) .07
Patient age at time of image, y
FAZ 0.00 (−0.01 to 0.00) .91
NP total −0.30 (−0.71 to 0.10) .14
NP posterior −0.02 (−0.04 to 0.00) .07
NP mid-periphery −0.11 (−0.31 to 0.09) .27
NP far-periphery −0.22 (−0.48 to 0.04) .09
NV total −0.04 (−0.08 to 0.00) .06
NV posterior 0.00 (−0.01 to 0.00) .16
NV mid-periphery −0.03 (−0.07 to 0.00) .06
NV far-periphery 0.00 (−0.01 to 0.01) .41
Diabetes type (2/1)
FAZ 0.11 (−0.03 to 0.25) .12
NP total −0.48 (−15.57 to 14.62) .95
NP posterior 0.63 (−0.11 to 1.37) .10
NP mid-periphery 4.45 (−2.71 to 11.61) .22
NP far-periphery −4.19 (−14.58 to 6.19) .43
NV total −1.59 (−3.73 to 0.56) .15
NV posterior −0.30 (−0.70 to 0.11) .15
NV mid-periphery −1.20 (−2.89 to 0.50) .17
NV far-periphery −0.08 (−0.43 to 0.27) .66
Race
Black/white
FAZ 0.05 (−0.07 to 0.17) .44
NP total 11.09 (−3.95 to 26.13) .15
NP posterior 0.03 (−0.63 to 0.70) .92
NP mid-periphery −0.03 (−6.22 to 6.16) .99
NP far-periphery 10.48 (−0.02 to 20.99) .05
NV total 2.32 (0.09 to 4.55) .04
NV posterior 0.18 (−0.13 to 0.49) .26
NV mid-periphery 1.50 (−0.31 to 3.32) .11
NV far-periphery 0.64 (0.18 to 1.10) .01
Asian/white
FAZ 0.24 (−0.19 to 0.68) .28
NP total 2.64 (−20.14 to 25.41) .82
NP posterior 0.60 (−0.74 to 1.93) .38
NP mid-periphery 4.77 (−10.06 to 19.59) .53
NP far-periphery −2.80 (−14.81 to 9.21) .65
NV total −0.01 (−0.66 to 0.64) .98
NV posterior 0.02 (−0.08 to 0.12) .67
NV mid-periphery 0.11 (−0.41 to 0.64) .67
NV far-periphery −0.14 (−0.28 to 0.00) .05
Hispanic/white
FAZ −0.01 (−0.46 to 0.44) .97
NP total −25.93 (−52.46 to 0.61) .06
NP posterior −0.63 (−1.56 to 0.29) .18
NP mid-periphery −10.38 (−24.33 to 3.57) .14
NP far-periphery −16.65 (−30.87 to −2.44) .02
NV total 0.12 (−1.36 to 1.60) .87
NV posterior −0.11 (−0.27 to 0.04) .13
NV mid-periphery 0.32 (−1.07 to 1.71) .65
NV far-periphery −0.07 (−0.32 to 0.18) .57
(continued)
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Discussion
This study analyzed UWF FA biomarkers for patients with dia-
betes and compared surface areas of NP and NV to demo-
graphic factors and characteristics of advanced DR. It also iden-
tified a threshold total area of NP that may be associated with
increased PDR risk. The results of this study show male sex,
black race/ethnicity, and presence or development of VH are
most associated with greater areas of NP and NV in patients
with diabetes. Also, eyes with at least 77.48 mm2 of total NP
may be associated with an increased risk of developing PDR.
There are numerous studies and surveys describing the demo-
graphic characteristics of patients diagnosed as having DR,28-30
but they are limited by analyses that only compare presence
or absence of disease and not incremental, quantifiable data
such as the areas of NP and NV at specific radii. With quanti-
fiable data, associations can be calculated, and the potential
practicality of the associations may be better understood.
The study’s results on sex and race/ethnicity match cur-
rent literature in that men and black individuals were most
strongly associated with having more advanced DR.29,30 Con-
founding factors could have contributed to these associa-
tions. For example, hypertension is associated with larger bio-
markers, especially NP and NV, and is also more prevalent in
men and black individuals.31,32 These unidentified comorbidi-
ties will need to be considered in future analyses of this data
set. National demographic data also indicate Hispanic pa-
tients tend to have more advanced disease.29,30 Although the
results of this study did not corroborate this finding, this
may be owing to the limited number of Hispanic patients.
Despite a greater proportion of black patients than previous
studies,8,11,13,17-19 there was a disproportionately low percent-
age of Hispanic patients. Thus, the negative association
between Hispanic race/ethnicity and NP area in the far
periphery demonstrated by this study must be interpreted
accordingly.
Race/ethnicity were more strongly associated with NP area
in the midperiphery and far periphery radii compared with total
NP area. Similarly, there were stronger associations between
race/ethnicity and NV in the far periphery. This was a surpris-
ing observation and may argue for the need to examine the far
periphery, instead of using a holistic judgment based on the
total retina observed. Our results were similar to those of Silva
et al,8,17,18 with far-peripheral pathology associated with in-
creased risk for worse DR severity.
Age had no consistent associations with any of the biomark-
ers. A similar finding was observed in a study by Chatziralli et al,33
which showed a significant positive association between DR
severity and age on univariate analysis in a study with 120 eyes
that lost significance on multivariate analysis. The researchers
hypothesized this result was likely because of the strong asso-
ciation between increased age and longer duration of diabetes,
making age a confounding variable. Diabetes type also had no
consistent associations, except type 1 diabetes was generally as-
sociated with larger biomarkers, especially NV. Studies indicate
differentVEGFgenepolymorphismsareassociatedwitheachdia-
betes type, and type 1 diabetes may be associated with a more
aggressive gene.34
Characteristics of advanced DR were also analyzed be-
cause relating these visually significant markers of advanced
disease with quantifiable biomarkers could help explain the
pathogenesis of PDR. In our study, there was a positive asso-
ciation between VH and NP at the midperiphery. In some pa-
tients with diabetes, retinal ischemia can initiate NV and vit-
reous hemorrhages. Although the far periphery is often
associated with the greatest areas of NP and subsequent NV,
the association demonstrated in the midperiphery, which in-
cludes the optic disc, matches initial RECOVERY study results.14
The lack of association between VH and NV might be owing
Table 2. Influence of Demographics on Biomarkers as Explored by Multiple Linear Regression Analysis
(continued)
Confounding factor Biomarker Coefficient (95% CI) P value
Other/white
FAZ 0.21 (−0.19 to 0.60) .30
NP total −0.91 (−39.90 to 38.09) .96
NP posterior −0.35 (−1.10 to 0.40) .35
NP mid-periphery 3.11 (−16.97 to 23.19) .76
NP far-periphery −4.57 (−24.49 to 15.36) .65
NV total −0.58 (−1.20 to 0.03) .06
NV posterior −0.04 (−0.13 to 0.06) .43
NV mid-periphery −0.37 (−0.83 to 0.09) .12
NV far-periphery −0.17 (−0.30 to −0.04) .01
Unknown/white
FAZ 0.15 (−0.26 to 0.55) .48
NP total 26.57 (−1.53 to 54.67) .06
NP posterior −0.24 (−0.85 to 0.37) .44
NP mid-periphery 11.73 (−5.70 to 29.17) .19
NP far-periphery 14.81 (−2.83 to 32.46) .10
NV total 0.03 (−0.68 to 0.74) .93
NV posterior −0.06 (−0.18 to 0.06) .31
NV mid-periphery 0.01 (−0.44 to 0.46) .96
NV far-periphery 0.08 (−0.24 to 0.41) .61
Abbreviations: FAZ, foveal avascular
zone; NP, nonperfusion;
NV, neovascularization.
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to the relatively small number of patients with VH (18 eyes total)
that also presented with areas of NV (10 eyes). Our results
showed no association between macular edema and NP or NV,
which is in contrast to published studies that show far-
periphery ischemia to be significantly associated.8,11,13 Analy-
ses with larger cohorts of patients with advanced DR charac-
teristics are necessary to elicit a better understanding of their
association with biomarkers.
Although the FAZ showed no strong association to any of
the variables considered, previous work has shown its clini-
cal significance. Balaratnasingam et al35 studied the FAZ in 95
eyes and found it to be significantly associated with visual acu-
ity. Sim et al36 found an enlargement of FAZ between 5% to 10%
compared with baseline per year in eyes with DR. With one of
the greatest areas of oxygen consumption per gram of tissue
in humans, the FAZ is one of the most susceptible areas to is-
chemic pathology. The contradiction between the presented
results and previous results might be because the previous
studies analyzed FAZ using optical coherence tomography and
7 standard retinal fields, while our study analyzed FAZ using
UWF FA. On UWF FA, the FAZ makes up a much smaller area,
so fine differences in FAZ may not be as effectively detected
via manual segmentation.
This study also identified a possible threshold area of total
NP of 77.48 mm2 for PDR risk (sensitivity 59.5% and specific-
ity 73.6%). Unlike the analysis completed by Nicholson et al,12
which also identified a threshold area of NP for PDR progres-
sion, our work did not measure disc areas but instead mea-
sured manually segmented areas of NP in millimeters squared.
Measuring in universal units could allow for more tangible in-
terpretation. Similar to Nicholson et al,12 we limited analysis
to total NP, especially given the lack of power for NV. The find-
ing of a threshold value that may be associated with disease
progression could indicate eyes that present with larger total
areas of NP may require more aggressive treatment to pre-
vent disease progression. Although analyses of the effects of
PRP or anti–vascular endothelial growth factor intravitreal in-
jections were not completed, the threshold could be used in
clinical practice as an objective marker for requiring interven-
tion. Current practice relies on subjective clinical evaluation
of a patient’s eyes to determine need for treatment, which is
prone to bias. Although this threshold value cannot bear clini-
cal weight without further research, it is hoped that quantifi-
able biomarkers may eventually help clinicians identify tan-
gible cutoffs to consider treatment. Also, the relatively low AUC
may improve with inclusion of other features and should be a
goal for subsequent analyses.
Insight Toolkit SNAP and proprietary software from Op-
tos that adjusts for warping were used to calculate biomark-
ers. Other techniques to account for warping have been de-
Table 3. Association of Advanced Diabetic Retinopathy Indicators With Biomarkers
as Explored by Multiple Linear Regression Analysis
Confounding factor Biomarker Coefficient (95% CI) P value
VH (yes/no)
FAZ 0.41 (−0.84 to 1.65) .52
NP total 30.00 (5.26 to 54.74) .02
NP posterior 2.82 (−0.36 to 6.01) .08
NP mid-periphery 12.85 (2.98 to 22.72) .01
NP far-periphery 15.34 (−2.62 to 33.30) .09
NV total −0.46 (−2.41 to 1.49) .64
NV posterior −0.23 (−0.48 to 0.01) .06
NV mid-periphery 0.02 (−1.63 to 1.68) .98
NV far-periphery −0.33 (−0.69 to 0.03) .07
DME (yes/no)
FAZ −0.13 (−0.29 to 0.03) .11
NP total −0.83 (−10.58 to 8.91) .87
NP posterior 0.23 (−0.25 to 0.71) .35
NP mid-periphery 0.20 (−3.84 to 4.24) .92
NP far-periphery −0.36 (−7.01 to 6.30) .92
NV total −0.86 (−2.06 to 0.33) .16
NV posterior −0.08 (0.22 to 0.07) .29
NV mid-periphery −0.53 (−1.53 to 0.47) .30
NV far-periphery −0.23 (−0.48 to 0.02) .08
At least 1 PPV
FAZ 0.16 (−0.40 to 0.73) .57
NP total 20.10 (−2.55 to 42.76) .08
NP posterior −0.02 (−1.06 to 1.02) .97
NP mid-periphery 5.29 (−2.42 to 13.01) .18
NP far-periphery 13.33 (−2.78 to 29.43) .10
NV total 5.30 (−0.36 to 10.96) .07
NV posterior 0.49 (−0.16 to 1.14) .14
NV mid-periphery 4.28 (−0.70 to 9.27) .09
NV far-periphery 0.52 (−0.24 to 1.28) .18
Abbreviations: DME, diabetic macular
edema; FAZ, foveal avascular
zone; NP, nonperfusion;
NV, neovascularization; PPV, pars
plana vitrectomy; VH, vitreous
hemorrhage.
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scribed; for example, Nicholson et al12 used a concentric ring
template to estimate disc areas. Consideration of distortion is
important when calculating retinal areas since as much as 10%
of an area could depend on its axial length.37 The Optos soft-
ware minimizes distortion by using an on-axis UWF image of
the posterior pole to transform peripheral images with elastic
deformation.21
The study analyzed UWF FA, but there are other imaging
modalities to consider that may yield similar results. Spectral-
domain optical coherence tomography angiography (OCTA) or
swept-source OCTA are widely available and may be a more fea-
sible option for most clinics. However, they do not provide a
widefield capture. Wide-angle OCTA does allow for a breadth
of capture similar to UWF FA, but studies are inconclusive re-
garding its efficacy vs UWF FA.38-40 Initial analyses indicate UWF
FA has slight superiority in sensitivity and specificity for de-
tecting NP and NV.38 Studies published within the last year sug-
gest wide-angle OCTA is the only follow-up testing necessary
for evaluating DR progression.39,40 Because UWF FA has been
established as a valid imaging technique for robust capture of
the retina, UWF FA images were used, but further analysis com-
paring wide-angle OCTA should be considered.
Regardless of imaging modality, the study suggests the im-
portance of UWF in clinical treatment design because UWF cap-
tures pathologic areas associated with demographic and dia-
betic risk factors not captured by the standard ancillary testing.
Identification of suggested higher risk populations (eg, male
sex, black race, and presence of VH) from this study in clini-
cal practice may indicate more frequent follow-up or aggres-
sive treatment to reduce risk of progression. This study com-
bines the more well-established tools for evaluating disease
(UWF FA, demographic risk factors, and visually significant pa-
thology) together with biomarkers, which may help deter-
mine who should be followed more closely. Also, this study may
indicate an association between certain demographic fea-
tures and biomarkers that could help elucidate the pathophysi-
ology for why certain populations are associated with greater
risk for progression.
Limitations
One main limitation of this study was the unrepresentative
breakdown of races, although it did have a larger percentage
of African American individuals than previous studies.8,11,13,17-19
Another limitation was the use of manual graders for segmen-
tation owing to potential variability and inaccuracy but should
have been minimized with confirmation and training by the
expert retinal specialist. Although images of poor quality were
excluded, artifacts, such as eyelashes, still could have caused
unintended variability. The quantification also assumed an eye
diameter of 24 mm, which could have affected surface
areas depending on actual axial lengths. Finally, a prospec-
tive study and not a cross-sectional retrospective study is war-
ranted. These results cannot be generalized owing to these
limitations.
Conclusions
Given the lack of statistical plan prior to study engagement,
unadjusted P values, and ascertainment and information bi-
ases, no statistical significance could be established. How-
ever, the associations between visually significant pathol-
ogy, demographics, and biomarkers found in this study may
suggest which populations are at higher risk for disease pro-
gression. More studies evaluating peripheral surface areas are
necessary to validate these findings.
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